Sugi Predict

Sugi Predict / Compounds / SCHEMBL2224060

SCHEMBL2224060

SCHEMBL2224060

CN1CCC(CNC(=O)CCCc2noc(C(F)(F)F)n2)(c2coc(-c3ccc(F)cc3)n2)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 12/20 0.38
▸ HDAC6 Q9UBN7 6/20 0.38
▸ HDAC8 Q9BY41 4/20 0.38
▸ HDAC7 Q8WUI4 4/20 0.38
▸ HDAC5 Q9UQL6 4/20 0.38
▸ HDAC9 Q9UKV0 3/20 0.38
▸ HDAC2 Q92769 2/20 0.38
▸ CHRM5 P08912 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ HDAC1 Q13547 3/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ NCOR2 Q9Y618 1/20 0.34
▸ USP2 O75604 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MCHR1 Q99705 3/20 0.33
▸ DRD3 P35462 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270279 0.82 HDAC4 (0.36) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL14297326 0.81 HPGD (0.34) HDAC6HDAC8CHRM5CHRM1CHRM3
SCHEMBL2223332 0.80 HDAC4 (0.36) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL2354493 0.79 HDAC4 (0.42) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL6977627 0.79 HDAC4 (0.63) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL2351016 0.78 GAA (0.43) HDAC4HDAC6HDAC7HDAC5LMNA
SCHEMBL2222138 0.77 HDAC4 (0.53) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL2222262 0.76 HDAC4 (0.36) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL2222463 0.74 TSHR (0.43) HDAC4HDAC6HDAC8HDAC7HDAC5
SCHEMBL6976493 0.73 HDAC4 (0.63) HDAC4HDAC6HDAC8HDAC7HDAC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120322827-A1 COMPOUNDS AND METHODS TEMPERO PHARAMCEUTICALS. INC. 2012-12-20 — — US claimed
WO-2013009812-A1 METHODS OF TREATMENT TEMPERO PHARMACEUTICALS, INC (US) 2013-01-17 — — WO disclosed
US-20120322827-A1 COMPOUNDS AND METHODS TEMPERO PHARAMCEUTICALS. INC. 2012-12-20 — — US disclosed
US-20120322827-A1 COMPOUNDS AND METHODS TEMPERO PHARAMCEUTICALS. INC. 2012-12-20 — — US disclosed
US-20120322827-A1 COMPOUNDS AND METHODS TEMPERO PHARAMCEUTICALS. INC. 2012-12-20 — — US disclosed
EP-2523560-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2012-11-21 — — EP disclosed
WO-2011088187-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed
WO-2011088187-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322827-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY HDAC4 2086/4885HDAC6 1991/4885HDAC8 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.